These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 20116636

  • 1. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M.
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M, Alimena G.
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [Abstract] [Full Text] [Related]

  • 3. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 4. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.
    Free Radic Biol Med; 2012 Aug 15; 53(4):643-8. PubMed ID: 22705364
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun 15; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 6. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol; 2010 Feb 15; 89(2):147-54. PubMed ID: 19690857
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug 15; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

  • 8. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP, Yang YS, Yao CY, Peng CT.
    Hemoglobin; 2009 Aug 15; 33(5):339-45. PubMed ID: 19814680
    [Abstract] [Full Text] [Related]

  • 9. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG, Nagler A.
    Expert Rev Anticancer Ther; 2014 Jul 15; 14(7):817-29. PubMed ID: 24641787
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators.
    Leuk Res; 2010 Sep 15; 34(9):1143-50. PubMed ID: 20451251
    [Abstract] [Full Text] [Related]

  • 12. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM.
    Oncologist; 2009 May 15; 14(5):489-96. PubMed ID: 19365094
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan 15; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

  • 18. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul 15; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL.
    Leuk Res; 2007 Dec 15; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.